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Abstract
Background: Bone Morphogenetic Protein (BMP)-7 is protective in different animal models of acute and chronic kidney
disease. Its role in human kidneys, and in particular hypertensive nephrosclerosis, has thus far not been described.
Methods: BMP-7 mRNA was quantified using real-time PCR and localised by immunostaining in tissue samples
from normal and nephrosclerotic human kidneys. The impact of angiotensin (AT)-II and the AT-II receptor
antagonist telmisartan on BMP-7 mRNA levels and phosphorylated Smad 1/5/8 (pSmad 1/5/8) expression was
quantified in proximal tubular cells (HK-2). Functional characteristics of BMP-7 were evaluated by testing its
influence on TGF-b induced epithelial-to-mesenchymal transition (EMT), expression of TGF-b receptor type I
(TGF-bRI) and phosphorylated Smad 2 (pSmad 2) as well as on TNF-a induced apoptosis of proximal tubular cells.
Results: BMP-7 was predominantly found in the epithelia of the distal tubule and the collecting duct and was less
abundant in proximal tubular cells. In sclerotic kidneys, BMP-7 was significantly decreased as demonstrated by
real-time PCR and immunostaining. AT-II stimulation in HK-2 cells led to a significant decrease of BMP-7 and
pSmad 1/5/8, which was partially ameliorated upon co-incubation with telmisartan. Only high concentrations of
BMP-7 (100 ng/ml) were able to reverse TNF-a-induced apoptosis and TGF-b-induced EMT in human proximal
tubule cells possibly due to a decreased expression of TGF-bRI. In addition, BMP-7 was able to reverse
TGF-b-induced phosphorylation of Smad 2.
Conclusions: The findings suggest a protective role for BMP-7 by counteracting the TGF-b and TNF-a-induced
negative effects. The reduced expression of BMP-7 in patients with hypertensive nephrosclerosis may imply loss of
protection and regenerative potential necessary to counter the disease.
Background
Bone Morphogenetic Protein (BMP)-7 has been found to
be renoprotective and to promote kidney regeneration in
several animal models [1]. This finding was also observed
in acute renal injury of the adult kidney as well as in
chronic kidney disease [2-4]. The following mechanisms
have been found to play a role in the effect of BMP-7:
1) regeneration of tubular epithelial cells by reversal of
the epithelial-to-mesenchymal transition (EMT) [4],
2) decrease of apoptosis in tubular epithelial cells [5] and
3) anti-inflammatory effects by decreasing the accumula-
tion of inflammatory cells [3,6] and an amelioration of
TNF-a-induced expression of pro-inflammatory
cytokines in proximal tubular cells [7].
However, these results have usually been obtained in
animal models, and data from human kidneys are scarce.
The available experiments in human tissue have shown a
tubular expression pattern of BMP-7 in normal kidneys
[8] and a reversibility of TGF-b-induced EMT by BMP-7
in proximal tubular cells [9], which was similar to the
results obtained in rodents. On the other hand, in contrast
with some prior animal data, some research has shown an
increased expression of BMP-7 in proximal tubular cells
in patients with proteinuria [10] and a failure to attenuate
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a TGF-b-induced EMT in primary or immortalised human
proximal tubule epithelial cells in vitro [11].
The aim of the present study was to comprehensively
investigate BMP-7 expression as well as its regulation
and function in normal and hypertensive sclerotic
human kidneys [12,13].
Methods
Patients and Tissues
Bioptic kidney samples for immunostaining were
obtained from 12 patients with clinically confirmed
nephrosclerosis. Control tissue was obtained from
patients undergoing surgical nephrectomy for neoplastic
kidney disease (n = 10).
Kidney tissue for real-time PCR was obtained from the
European Renal cDNA Bank [14]. We included 32 sam-
ples from patients with nephrosclerosis and 10 samples
from pretransplant biopsies of living and deceased
donors. None of the donors had relevant proteinuria,
decreased renal function or arterial hypertension [14].
The characteristics of patients with nephrosclerosis are
displayed in Table 1.
The use of human samples was approved by the ethi-
cal committee of the Georg August University Göttin-
gen (Ref-No #11/10/04).
Cell culture experiments
The human proximal tubular epithelial cell line HK-2
was cultured in serum free complete Quantum 286
medium (PAA, Pasching, Germany) [15]. Cells were
made quiescent 24 hours prior to stimulation by incuba-
tion with DMEM medium without additives (Invitrogen,
Carlsbad, USA).
Immunofluorescence
Double immunofluorescence (DIF) with anti BMP-7
(goat polyclonal IgG, Santa Cruz, USA) was performed
to identify the expression localisation of BMP-7 inside
the normal and nephrosclerotic kidney. Counterstaining
with Aquaporin-1 (AQ-1, diluted 1:50; rabbit polyclonal
IgG, Alpha Diagnostic, San Antonio, USA) was used to
identify the proximal and distal tubule, and counter-
staining with Aquaporin-2 (AQ-2, diluted 1:50, rabbit
polyclonal IgG, Calbiochem, San Diego, USA) was used
to identify the collecting duct [16]. Double staining was
performed using a combination of rhodamine red for
BMP-7, and FITC (green) for AQ-1 and -2. Double-
labelled cells resulted in orange staining. Negative
controls were included in all experiments by exclusive
incubation with the second antibody.
To analyse EMT, HK-2 cells (10,000/ml) were stained
for the epithelial marker zona occludens-1 (ZO-1, 1:25,
rabbit polyclonal IgG, Santa Cruz, Santa Cruz, USA)
and the mesenchymal marker a-smooth muscle actin
(a-sm actin, 1:250, rabbit monoclonal IgG, Novus Biolo-
gicals, Littleton, USA) after stimulation for 48 hours
with TGF-b (10 ng/ml) in the presence or absence of
BMP-7 (10, 100 ng/ml).
To analyse the influence of BMP-7 on cell death,
HK-2 cells (10,000/ml) were stained for annexin-V
(Annexin-V-FLUOS Staining Kit, Roche, Mannheim,
Germany) after stimulation with TNF-a (20 ng/ml) for
24 hours in the presence or absence of BMP-7 (1, 10,
100 ng/ml, R&D, Minneapolis, USA). Staining for
TGF-b receptor type I (TGF-bRI, 1:50, rabbit polyclonal
IgG, Santa Cruz, Santa Cruz, USA) was performed after
incubation with BMP-7 (100 ng/ml) for 48 hours.
In both kidney slices and HK-2 cells, cell nuclei (blue)
were identified by counterstaining with 4,6-diamino-
2-phenylindolyl-dihydrochloride (DAPI; Vector Labs,
Burlingame, USA). Staining was visualised by epifluores-
cence microscopy (Zeiss Axiovert S100TV, Oberkochen,
Germany). Quantification of cell staining intensity was
given in grey values by the software AnalySIS (Olympus
Soft Imaging Solutions GmbH, Münster, Germany). For
comparison between the single stimulation experiments,
the same number of cells was evaluated.
Immunohistochemistry
To identify differences in the BMP-7 expression pattern of
sclerotic and normal kidneys, immunohistochemistry
(IMH) was performed. The IMH of BMP-7 was performed
Table 1 Characteristics of patients with nephrosclerosis
Real time PCR (European Renal cDNA Bank) Immunohisto-chemistry
Number of patients 32 12
Age in years (median, IQR) 55 (48-64) 64.5 (58.5-67.5)
Male/female (n) 25/7 9/3
Disease duration (years) n.a. 14 (7-25.8)
Creatinine Clearance (ml/min) (median, IQR) 51.8 (32.8-61.8) 39.0 (15.5-56.4)
Proteinuria (g/day) (median, IQR) 2.3 (0.4-3.1) 0.5 (0.2-1.4)
Degree of interstitial fibrosis (%) (median, IQR) n.a. 43.6 (39.8.-48.5)
Legend: IQR, interquartile range; n.a., not available
Reference values: Creatinine Clearance: 80-140 ml/min.,
Proteinuria: <150 mg/day
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as described [16]. An antibody against human BMP-7 (see
DIF) was used as the primary antibody, and rabbit anti-
goat biotinylated Ig antibody (DAKO, Glostrup, Denmark)
was used as the secondary antibody. Negative controls
were included in all experiments, and for these, the first
antibody was omitted. Nuclear counterstaining was per-
formed using hematoxylin. Intensity of BMP-7 expression
in tubules were evaluated by an established semiquantita-
tive score as follows: 0 = no staining; 1 = weak staining;
2 = moderate staining and 3 = strong staining [17]. For
evaluation, five visual field areas per kidney slice were
analysed, and the results are presented as the mean ±
standard error.
Real-time PCR
Real-time RT-PCR was performed on a TaqMan ABI
7700 Sequence Detection System (PE Biosystems, Wei-
terstadt, Germany) using heat-activated TaqDNA poly-
merase (Amplitaq Gold; PE Biosystems). After an initial
hold of two minutes at 50°C and ten minutes at 95°C,
the samples were cycled 40 times at 95°C for 15 seconds
and 60°C for 60 seconds. Quantification was performed
using the standard curve approach applying serial dilu-
tions of standard cDNA for each target and reference
gene. All samples, controls and patients, were analysed
in the same run in technical replicates with high repro-
ducibility (threshold cycle (Ct) difference <0.4; mean Ct
of each sample <32) [14,16]. To exclude the possibility
of genomic contamination, we conducted a “no-RT con-
trol” in every single PCR using non-reverse transcribed
mRNA instead of cDNA. Only real-time PCRs with a
negative “no-RT control” were evaluated.
Quantification of BMP-7 mRNA transcription in kid-
ney tissue samples was determined separately for glo-
meruli and for the tubulointerstitium after manual
microdissection [14]. Thereby, tubulointerstitial and
glomerular samples were from the same individuals.
Quantification of BMP-7 transcription in HK-2 cells by
real-time PCR was done after stimulation with angioten-
sin-II (AT-II, 10-7, 10-5 and 10-3 M, Sigma Aldrich, St.
Louis, USA), with the angiotensin-II receptor antagonist
telmisartan (10, 20 and 30 μM, Boehringer Ingelheim,
Germany) or both in combination (10-3 M AT-II + 10,
20 and 30 μM telmisartan) for 12 hours [14,16].
To evaluate EMT in human HK-2 cells, quantification of
the epithelial marker ZO-1, and E-cadherin as well as the
mesenchymal marker a-sm actin and S100A4 was done
after stimulation with TGF-b (10 ng/ml), BMP-7 (100
ng/ml) or both in combination (10 ng/ml TGF-b + 100
ng/ml BMP-7). Moreover, TGF-bRI was determined after
stimulation with 1, 10 and 100 ng/ml BMP-7 in HK-2
cells. Total RNA from both tissue and cells was extracted
using the Qiagen RNeasy Mini Kit, including a treatment
with RNase-Free DNase (both Qiagen, Hilden, Germany)
and reverse transcribed using random priming. Oligonu-
cleotides were obtained from Primerdesign (Southampton,
UK) and are listed in Table 2. The housekeeping gene
Peptidyl-Prolyl-Isomerase-A (PPIA) was chosen because
its expression level was comparable to BMP-7 and vali-
dated in kidney tissue with a constant expression [18].
Protein extraction and immunoblotting
Western blot analysis of phosphorylated Smad 1/5/8
(pSmad 1/5/8, diluted 1:1000; rabbit polyclonal IgG, Cell
Signalling, Beverly, USA) and phosphorylated Smad 2
(pSmad 2, diluted 1:1000; rabbit polyclonal IgG, Cell
Signaling, Beverly, USA) was performed as previously
described [17]. Polyclonal goat anti-rabbit IgG antibody
(1:2000, DAKO, Glostrup, Denmark) was used as
secondary antibody. Phosphorylated Smad 1/5/8 was
Table 2 Oligonucleotides
mRNA Gene Bank accession number Oligonucleotide (5’ - 3’) (up/down) bp
PPIA NM 021130 TGG GCA ACA TAG TGA GAC G 139
TGT ACA GTG GCA TGA TAA TAG C
BMP-7 NM 001719 CCT CCA TTG CTC GCC TTG 114
TAT GCT GCT CAT GTT TCC TAA TAC
E-cadherin NM 00436 CAT GAG TGT CCC CCG GTA TC 89
CAG TAT CAG CCG CTT TCA GA
ZO-1 NM 003257 AAA CAA GCC AGC AGA GAC C 95
CGC AGA CGA TGT TCA TAG TTT C
a-sm-actin NM 001613 AAG CAC AGA GCA AAA GAG GAA T 76
ATG TCG TCC CAG TTG GTG AT
S100A4 NM 002961 TCT TTC TTG GTT TGA TCC TGA CT 130
AGT TCT GAC TTG TTG AGC TTG A
TGF-bRI NM 004612 TGA CTG AAG GCT GCT CTG G 125
CAT CTG CTC AAT CTC CAA ACT TG
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determined in HK-2 cells (1,000,000/ml, 25 μg/blot) after
stimulation with AT-II (10-3 M) for 36 hours. Phosphory-
lated Smad 2 was determined in HK-2 cells (1,000,000/
ml, 25 μg/blot) after stimulation with 10 ng/ml TGF-b
alone and in combination with BMP-7 (100 ng/ml).
FACS analysis of apoptosis
FACS analysis was performed to determine the rate of
apoptosis in HK-2 cells [19]. Cells were stimulated with
either TNF-a (20 ng/ml, R&D, Minneapolis, USA),
BMP-7 (1, 10, 100 ng/ml), or both for 24 hours. Apop-
totic cells were classified as annexin-V positive and pro-
pidium iodide negative using a FACScan flow cytometer
(Becton Dickinson, San Jose, CA).
Statistical analysis
Statistical analysis was performed using SigmaStat
(Systat Software Inc., San Jose, USA). Real-time PCR
data of BMP-7 expression in the whole kidney were
evaluated using the Kruskal-Wallis test followed by the
Mann-Whitney-U test for comparison. These data and
the clinical data were presented in median with quar-
tiles (25th and 75th percentile). The results of the cell
culture experiments were presented as the means with
standard errors. Significant changes were evaluated
using Student’s t-test due to the sample sizes (mini-
mum: n = 3) and can only be regarded as descriptive.
For both statistical methods, p-levels of < 0.05 were
regarded to be significant.
Results
BMP-7 mRNA level is decreased in nephrosclerotic
compared to normal kidneys
BMP-7 mRNA was significantly reduced in the tubuloin-
terstitium of patients with nephrosclerosis (relative med-
ian quantity with quartiles: 0.25 (0.14 - 0.42)) compared
to normal kidneys (0.69 (0.28 - 0.83), p < 0.01) (Figure 1).
Levels of glomerular BMP-7 mRNA did not signifi-
cantly differ among patients with nephrosclerosis (0.26
(0.14 - 0.54)) compared to those without kidney diseases
(0.19 (0.13 - 0.30), p = 0.561) (Figure 1).
BMP-7 is mainly expressed in the distal tubule and
collecting duct
In normal kidneys, BMP-7 protein was found to be loca-
lised in the epithelium of the distal tubule and the col-
lecting duct but was less abundant in the proximal
tubular cells or glomeruli. Expression in the distal
tubules was suggested by parallel binding of BMP-7 and
AQ-1 in tubules with smaller cuboidal cells and larger
lumen. Proximal tubules with prominent cuboidal
epithelial cell lining and the smaller lumen showed
higher AQ-1 than BMP-7 expression (Figure 2). Double
immunofluorescence (DIF) with BMP-7 and AQ-2
showed parallel expression, revealing expression of
BMP-7 in the collecting duct (Figure 3). As illustrated
by double immunofluorescence (Figure 2, 3, 4) and
immunohistochemistry (Figure 5), localisation of the
BMP-7 expression was unchanged in patients with
Figure 1 Real-time PCR analysis: the BMP-7 mRNA level is decreased in the tubulointerstitium but not in the glomeruli of patients
with sclerotic compared to normal kidney tissue. Real time PCR with BMP-7 in normal kidneys (n = 10) and those from patients with
nephrosclerosis (n = 32), housekeeping gene PPIA. Relative BMP-7 mRNA transcription in the tubulointerstitium and glomeruli of the kidneys are
shown. BMP-7 mRNA was significantly decreased in the tubulointerstitium of patients with nephrosclerosis compared to normal kidneys (p <
0.01; Kruskal-Wallis test followed by Mann-Whitney-U test). The BMP-7 mRNA level in the glomeruli did not differ significantly. The results are
displayed as medians with quartiles.
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nephrosclerosis, but the mean intensity was significantly
lower (0.86 ± 0.17) compared to controls (2.5 ± 0.07)
(95% confidence interval (CI) 0.23 - 3.10, p < 0.05).
Regulation of BMP-7 expression by the
renin-angiotensin system
To examine the interaction of BMP-7 with the renin-
angiotensin system, BMP-7 mRNA level in HK-2 cells was
quantified by real-time PCR (18 μg/ml cDNA; 25 - 30
cycles) after stimulation with AT-II, telmisartan or both in
combination for 12 hours. As shown in Figure 6, the tran-
scription of BMP-7 was significantly decreased after
stimulation with 10-3 M AT-II compared to unstimulated
cells (95% confidence interval (CI) 66.1 - 103.3, p < 0.001)
and increased after stimulation with 30 μM telmisartan
(95% CI 29.6 - 146.2, p < 0.01). The stimulation with a
combination of AT-II and telmisartan showed higher
BMP-7 mRNA levels compared to AT-II alone; the differ-
ence was, however, not significant.
BMP-7 is able to reverse EMT in human
proximal tubule cells (HK-2)
To analyse the influence of BMP-7 on EMT in human
proximal tubule cells, the expression of epithelial and
BMP-7 & Aquaporin-1 (x200)
Aquaporin-1 (x200) BMP-7 (x200)
Negative Control
A B
C D
Figure 2 Immunofluorescence of BMP-7 and Aquaporin 1 in normal kidneys revealing expression in distal tubules and proximal
tubular cells. Double immunofluorescence of BMP-7 with aquaporin-1 (AQ-1): A) AQ-1 is green (FITC), B) BMP-7 staining is red (rhodamine red),
C) double labelling of BMP-7 and AQ-1 is orange and nuclei is blue (DAPI). Parallel binding of BMP-7 and AQ-1 is seen mainly in tubules with
smaller cuboidal cells and larger lumen indicating expression in distal tubules (small arrow) and less in proximal tubule cells (bulky arrow).
Staining was low in the glomeruli. Original magnification: × 200. D) Negative control × 100.
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mesenchymal marker were determined after stimulation
with BMP-7 alone or in combination with TGF-b.
Stimulation of human proximal tubule cells (HK-2) with
TGF-b (10 ng/ml) alone induced EMT as demonstrated
by morphological transformations of epithelial into
fibroblastoid cells (Figure 7). This morphological obser-
vation is underscored by the lower mRNA level of the
epithelial markers ZO-1 and E-cadherin and higher
transcription of the mesenchymal markers a-sm-actin
and S100A4 (Figure 8).
Co-stimulation of TGF-b and BMP-7 led to a reversal of
the prior morphological transformation with a predomi-
nant epithelial phenotype (Figure 7). The reversal of EMT
was further demonstrated by significantly increased
mRNA levels of E-cadherin (95% CI: 32.2 - 17.6, p <
0.001), by a tendency for increased mRNA levels of ZO-1
(95% CI: 0.5 - 56.5, p = 0.05) and by significantly decreased
levels of a-sm-actin (95% CI: 28.1 - 93.8, p < 0.001) and
S100A4 (95% CI: 9.6 - 34.7, p < 0.05). In analogy, similar
changes could be detected for the protein level of ZO-1
(95% CI: 5.7 - 69.1, p < 0.01) and a-sm-actin (95% CI:
284.7 - 859.6, p < 0.05) (Figure 8). Both the expression of
ZO-1 and a-sm-actin showed dose-dependent effects. Sig-
nificant changes in both protein and mRNA level were
observed only after stimulation with a concentration of
100 ng/ml BMP-7. BMP-7 alone did not substantially
influence the mRNA level of ZO-1, E-cadherin, a-sm-
actin and S100A4 (Figure 8), nor did it effect the protein
Figure 3 Immunofluorescence of BMP-7 and Aquaporin 2 in normal kidneys showing expression in the collecting duct. Double
immunofluorescence of BMP-7 with aquaporin-2 (AQ-2): A) AQ-2 is green (FITC), B) BMP-7 staining is red (rhodamine red), C, D) double-labelling
of BMP-7 and AQ-2 is stained orange (C: × 200, D: × 400) and nuclei are blue (DAPI). Parallel binding of BMP-7 and AQ-2 revealing expression of
BMP-7 in the collecting duct. Negative control: see Figure 2D. Original magnification: × 200 and × 400.
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Figure 5 Immunohistochemistry of BMP-7 with unchanged localisation, but lower expression levels in patient with nephrosclerosis
compared to normal kidneys. Immunostaining for BMP-7 was done in 10 normal kidneys (A - C) and in 12 kidneys from patients with
nephrosclerosis (D - F). Expression levels of BMP-7 were low in all examined kidney slices. BMP-7 is located mainly endoluminally in the normal
kidney (A: × 400; B: × 1000). In kidneys of patients with nephrosclerosis, localisation of BMP-7 expression was unchanged, but lower than in the
control kidneys (D: × 400; E: × 1000). Negative controls did not show any staining (C, F).
Figure 4 Immunofluorescence of BMP-7 and Aquaporin 1 and Aquaporin 2 in nephrosclerotic kidneys showing decreased expression
of BMP-7. Double immunofluorescence of BMP-7 with aquaporin-1 (AQ-1) and aquaporin-2 (AQ-2): BMP-7 staining is red (rhodamine red, A, B),
double-labeling of BMP-7 and AQ-1 (C) or AQ-2 (D) is stained organge. Expression of BMP-7 was lower than in the control kidneys demonstrated
by the lower staining intensity of BMP-7 despite a longer exposure time and therewith a stronger intensity of AQ-1 and AQ-2. Original
magnification: × 200.
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level of ZO-1 and of a-sm-actin compared to unstimu-
lated cells (= 100%) (Figure 7).
Decreased expression of pSmad 1/5/8 after
stimulation with BMP-7
To further verify the decrease of BMP-7 by angiotensin-
II, we examined the expression of phosphorylated Smad
1/5/8 as intracellular pathway mediators of BMP-7 by
western blotting (n = 3). In concordance with the
decreased BMP-7 expression by AT-II, phosphorylated
Smad 1/5/8 was significantly decreased in HK-2 cells
after stimulation with 10-3 mM AT-II to 54.8 ± 9.8% of
the unstimulated controls (= 100%, 95% CI: 21.0 - 70.2,
p < 0.05) (Figure 9A).
BMP-7 decreases TGF-b Receptor type I in HK-2 cells
To test the hypothesis that reversal of EMT by BMP-7
may be mediated by the down-regulation of TGF-b
Receptor type I (TGF-bRI) expression, this expression
was analysed after stimulation of HK-2 cells with BMP-7.
Expression of TGF-bRI was decreased after stimulation
with BMP-7 in a dose-dependent manner compared to
unstimulated cells (= 100%). This was demonstrated at
the protein level by immunofluorescence (Figure 10) and
at the mRNA level by real-time PCR (1 ng/ml: 92.98 ±
21.60%, 10 ng/ml: 39.29 ± 2.60%, 100 ng/ml: 25.71 ±
8.37%, data not shown). Thereby, stimulation with 100
ng/ml leads to a significant decrease of TGF-bRI expres-
sion at both the protein (95% CI: 27.3 - 75.6, p < 0.01)
and the mRNA level (95% CI: 53.5 - 95.1, p < 0.01) com-
pared to unstimulated HK-2 cells (Figure 10). Moreover,
the expression pattern of TGF-bRI changed after stimula-
tion with BMP-7 to a localisation that was more intracel-
lular than on the cell surface.
Decreased pSmad-2 expression in HK-2 cells after
stimulation with BMP-7
To further test the hypothesis that the decreased expression
of the TGF-b receptor type I by BMP-7 may have func-
tional consequences, phosphorylated Smad 2 was deter-
mined by western blotting after stimulation with TGF-b in
presence or absence of BMP-7. Compared to unstimulated
HK-2 cells, phosphorylated Smad 2 was increased after sti-
mulation with TGF-b alone (323.9 ± 96.4%) and signifi-
cantly decreased after co-stimulation with TGF-b and
BMP-7 (95% CI: 34.8 - 52.8, p < 0.05; Figure 9B).
BMP-7 influence on TNF-a induced apoptosis
Since BMP-7 is known to have protective effects on tub-
ular epithelial cells, we examined the influence of BMP-
Figure 6 BMP-7 mRNA level in HK-cells is decreased after stimulation with angiotensin-II and increased after stimulation with
telmisartan. BMP-7 mRNA level in the proximal tubule cell line HK-2 was determined by real-time PCR (housekeeping gene PPIA) after
stimulation with angiotensin-II (10-7, 10-5, 10-3 M) and telmisartan (10, 20, 30 μM) or with both combined for 12 hours (n = 12). BMP-7 mRNA
level is significantly decreased after stimulation with 10-3 M AT-II (p < 0.001) and increased after stimulation with 30 μM telmisartan (p < 0.01).
Co-stimulation of AT-II and telmisartan showed non-significantly increased BMP-7 mRNA levels compared to stimulation with AT-II alone. The
results are presented as the mean % of unstimulated cells ± standard error.
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7 on cell death and apoptosis in proximal tubule cells
(HK-2) after stimulation with TNF-a alone and in com-
bination with BMP-7. Apoptotic cells were detected by
FACScan (FACS) counting annexin-V positive and pro-
pidium iodide negative cells (Figure 11A): TNF-a
(20 ng/ml): 386.6 ± 41.3%; TNF-a (20 ng/ml) + 1 ng/ml
BMP-7: 356.1 ± 53.3%; + 10 ng/ml: 272.0 ± 28.9%; +
100 ng/ml: 173.2 ± 48.4%, 95% CI: 57.0 - 369.8%, p <
0.05), each compared to unstimulated cells.
The influence of BMP-7 on TNF-a induced cell death of
HK-2 cells was determined by immunofluorescence after
staining for annexin-V (Figure 11B). Stimulation of the
proximal tubule cells with 20 ng/ml TNF-a led to cell
death rates of 302.2 ± 1.5% compared to unstimulated
controls. Co-stimulation with a combination of TNF-a
(20 ng/ml) and BMP-7 (100 ng/ml) resulted in signifi-
cantly lower cell death rates than those observed with
TNF-a stimulation alone (95% CI: 52.7 - 189.3%, p <
0.05). Thus, the effect was dose-dependent: TNF-a + 1
ng/ml BMP-7: 318.0 ± 2.1%; + 10 ng/ml BMP-7: 283.4 ±
6.4%; +100 ng/ml BMP-7: 181.2 ± 0.7%).
BMP-7 alone did not substantially induce cell death
(DIF, 100 ng/ml: 97.5 ± 3.9%) or apoptosis (FACS, 100
ng/ml: 152.34 ± 5.9%).
Discussion
In this study, expression, regulation and function of
BMP-7 was compared in human hypertensive nephro-
sclerotic versus normal kidneys. Our results demon-
strated the following: 1) renal BMP-7 is decreased in
human hypertensive nephrosclerosis; 2) BMP-7 tran-
scription is regulated by the renin-angiotensin system
(AT-II vs. telmisartan) in vitro; 3) BMP-7 is able to
reverse TNF-a- and TGF-b-induced effects in human
Figure 7 BMP-7 reverses TGF-b-induced EMT detected by immunofluorescence. BMP-7 reverses TGF-b-induced EMT as demonstrated by
immunofluorescence of ZO-1 (A) and a-sm actin (B) in human proximal tubular cells (HK-2, n = 3). Stimulation with TGF-b alone (10 ng/ml) led
to a distinctive morphological transformation into fibroblastoid cells in combination with a lowered expression of ZO-1 (A) and a higher
expression of a-sm actin (B). Reversal of EMT was demonstrated by co-stimulation of HK-2 cells with TGF-b (10 ng/ml) and BMP-7 (10, 100 ng/
ml) showing epithelial morphology. Co-Stimulation with 10 ng/ml TGF-b and 100 ng/ml BMP-7 were leading to a significantly higher expression
of ZO-1 (p < 0.01; A) and lower expression of a-sm-actin (p < 0.001; B) compared to TGF-b stimulation alone. BMP-7 alone did not substantially
influence the expression of ZO-1 and a-sm-actin. Values were evaluated by determination of the staining intensity per cell using Student’s t-test
and are presented as % of unstimulated cells.
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proximal tubule cells, albeit only high concentrations;
and 4) BMP-7 decreased TGF-bRI expression.
BMP-7 localisation in normal kidneys and nephrosclerosis
BMP-7 was found to be expressed predominantly in the
epithelium of the distal tubule, the collecting duct and
less in the proximal tubular cells in normal kidneys.
This expression pattern is concordant with recently
published data, demonstrating the same expression
pattern in normal human kidneys [8]. We found that
localisation of BMP-7 expression was unchanged in
human hypertensive nephrosclerosis, but expression was
reduced, as demonstrated by immunostaining and real-
time PCR. Our results are in accordance with findings
in animals, where the renal BMP-7 expression was
reduced in several kidney disease models, including
acute ischemic renal injury, tubulointerstitial fibrosis
and diabetic nephropathy [2,20,21]. In contrast, pre-
vious investigations by Rudnicki et al. in proteinuric
patients showed an increase of BMP-7 expression in
proximal tubule cells [10]. Due to the heterogeneity of
the possible underlying kidney disease [10] in the dif-
ferent studies, it is difficult to assess and compare
these findings. Moreover, a reason for the discrepancy
of the results could be disparities in the stage of exam-
ined kidney disease. Thus, progression of kidney fibro-
sis is associated with a concomitant loss of BMP-7
expression in later stages of kidney disease [22].
Experiments with streptozotocin-induced diabetes in
rodents demonstrated decreased renal expression of
BMP-7 to 50% of its original level at week 15, and up
to 10% of the control animals by week 30 [22]. This, in
Figure 8 Real time PCR indicating reversal of TGF-b induced EMT by BMP-7. The mRNA level of the epithelial marker ZO-1 and E-cadherin
and the mesenchymal marker a-sm-actin and S100A4 were analysed after stimulation of HK-2 cells with TGF-b alone, BMP-7 alone or both in
combination (n = 3). There was a decrease of ZO-1 and E-cadherin and an increase of a-sm-actin and S100A4 mRNA after stimulation with TGF-
b alone, while no significant effect was seen after stimulation with BMP-7 alone. Co-stimulation of TGF-b and BMP-7 led to a significant increase
of ZO-1 (p < 0.001) and E-cadherin (p = 0.05) as well as a decrease of a-sm-actin (p < 0.001) and S100A4 mRNA (p < 0.05) compared to TGF-b
alone. The results were analysed by Student’s t-tests and are displayed as % of unstimulated cells.
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turn, could be due to the TGF-b induced down-regula-
tion of BMP-7 as demonstrated in proximal tubule
cells [22].
BMP-7 and the role of the renin-angiotensin system
To further test our hypothesis of BMP-7 involvement in
the development of human hypertensive nephrosclerosis,
we performed tissue culture experiments. In preliminary
experiments, we were able to detect BMP-7 mRNA in
primary isolated human distal tubule cells [23], but the
number of cells were limited; moreover, we were not
able to cultivate these cells long enough to perform
stimulation experiments. Due to the unavailability of
human distal tubule cell lines, we used the human prox-
imal cell line HK-2, although results on BMP-7 mRNA
transcription in proximal tubular epithelial cells are con-
troversial. Whereas Wetzel et al. failed to show any
BMP-7 mRNA in primary and immortalised (HK-2)
proximal tubule cells [8], BMP-7 mRNA was detected
by Rudnicki et al. [10]. In our experiments, BMP-7 tran-
scription in HK-2 cells was present, but copy number
was found to be low. Despite the low mRNA level,
BMP-7 was significantly decreased after stimulation with
AT-II, which could explain the lower BMP-7 expression
in the kidneys of patients with hypertensive nephro-
sclerosis. The effect may be evident from the decreased
expression of the pSmads 1/5/8 after stimulation with
angiotensin-II. However, the Smad complex 1/5/8 is
also activated by pro-fibrotic BMPs (e.g., BMP-2, -4)
and the exact regulation is due to several confounding
factor [24,25].
Increased BMP-7 transcription after co-stimulation
with AT-II and the angiotensin-II receptor antagonist
telmisartan may, in part, explain the protective effects
Figure 9 Figure 9A - Smad 1/5/8 is decreased by angiotensin-II. Western Blotting was performed in HK-2 cells for phosphorylated Smad
1/5/8 after stimulation with AT-II (10-3 mM, n = 3). Phosphorylated Smad 1/5/8 was significantly decreased in HK-2 cells after stimulation with
AT-II (p < 0.05). Figure 9B - BMP-7 attenuates TGF-b induced pSmad 2. Western blotting was performed in HK-2 cells for phosphorylated Smad 2
after stimulation with TGF-b alone (10 ng/ml) and TGF-b in combination with BMP-7 (100 ng/ml, n = 3). Phosphorylated Smad 2 was increased
after stimulation with TGF-b alone and significantly decreased after stimulation with TGF-b in combination with BMP-7 (p < 0.05).
Bramlage et al. BMC Nephrology 2010, 11:31
http://www.biomedcentral.com/1471-2369/11/31
Page 11 of 14
of these drugs in kidneys. However, significantly
increased BMP-7 mRNA level was seen after stimula-
tion with telmisartan alone, revealing an AT-II inde-
pendent effect of telmisartan on BMP-7 expression.
These findings are in line with former studies,
although most authors have focused primarily on the
telmisartan-induced decrease of inflammatory cyto-
kines and less on protective growth factors. Hence,
AT-II independent effects of telmisartan were
described to decrease TNF-a induced expression of
interleukin-6 in vascular smooth muscle cells [26], as
well as the expression of monocyte chemoattractant
protein 1 (MCP-1, CCL-2) and its receptor CCR2 in
peripheral blood monocytes [27].
BMP-7 effect on EMT
Thus far, the data on the reversibility of EMT by BMP-7 in
human kidneys are controversial. Although research by Xu
[9] and Veerasamy [28] showed that BMP-7 attenuated
TGF-b-induced EMT in human proximal tubule cells
(HK-2), Dudas was not able to confirm these results in
primary and immortalised human proximal tubule cells
[11]. Our functional data showed that BMP-7 was able to
reverse the TGF-b-induced EMT in human proximal
tubule cells by using high concentrations of recombinant
BMP-7 (100 ng/ml). One possible mode of action can be
the decreased expression of the TGF-b receptor type I,
which may also contribute to the reversal of EMT by
BMP-7. Thereby, the attenuated TGF-b signalling may be
caused by the decreased expression level as well as by the
decreased receptor expression on the cell surface. This
hypothesis may be in line with previous findings suggest-
ing that TGF-b R1 is internalised in clathrin-coated vesi-
cles and that the process of being expressed on the cell
surface plays an important regulatory role in TGF-b sig-
nalling [29]. The functional aspect may be demonstrated
by the decreased expression of phosphorylated Smad 2
after stimulation with TGF-b and BMP-7 compared to
TGF-b alone.
In contrast to Dudas [11], Xu et al. and our working
group used concentrations as high as 100 ng/ml BMP-
7 to attenuate TGF-b-induced EMT in HK-2 cells [9].
Figure 10 BMP-7 decreases expression of TGF-b receptor type I. Expression of TGF-b receptor type I after stimulation with BMP-7 (1, 10,
100 ng/ml) detected by double immunofluorescence: quantification of cell staining intensity was given in grey values by the software AnalySIS.
Expression rate is changed compared to unstimulated cells, concomitant with reduced staining intensity (100 ng/ml: p < 0.01). Original
magnification: × 1000. Results were analysed by Student’s t-test and are displayed as the % of unstimulated cells in the mean ± standard error.
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This high dose of BMP-7 may have inhibited the sys-
temic administration as a therapeutic option for
chronic kidney disease. However, of course, in vitro
studies in cell lines are not necessarily transferable to
in vivo studies in organisms.
BMP-7 effect on apoptosis
In addition, data from our study revealed that BMP-7
counteracts TNF-a-induced apoptosis in human proximal
tubule cells. These results in human cells are in accor-
dance with those reported by Vukicevic and co-workers,
who demonstrated decreases in apoptotic cells in BMP-7
treated subjects in rodents with acute renal failure [3].
However, again, high concentrations of BMP-7 were
necessary to achieve significant changes.
Conclusions
Our findings suggest a protective role of BMP-7 by
counteracting TGF-b and TNF-a negative effects in
vitro, although high concentrations of BMP-7 are neces-
sary. In agreement with the findings in animal studies,
the reduced expression of BMP-7 in patients with
hypertensive nephrosclerosis may imply a loss of protec-
tion and regenerative potential necessary to counter the
disease. The decrease may be in part induced by angio-
tensin-II and attenuated by telmisartan.
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